Cargando…
Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study
BACKGROUND: The frequency of antibodies in autoimmune encephalitis (AIE) may vary in different populations, however, data from developing countries are lacking. To describe the clinical profile of AIE in Brazil, and to evaluate seasonality and predictors of AIE in adult and pediatric patients. METHO...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634608/ https://www.ncbi.nlm.nih.gov/pubmed/37954587 http://dx.doi.org/10.3389/fimmu.2023.1256480 |
_version_ | 1785132856660459520 |
---|---|
author | de Freitas Dias, Bruna Fieni Toso, Fabio Slhessarenko Fraife Barreto, Maria Eduarda de Araújo Gleizer, René Dellavance, Alessandra Kowacs, Pedro André Teive, Helio Spitz, Mariana Freire Borges Juliano, Aline Januzi de Almeida Rocha, Letícia Braga-Neto, Pedro Ribeiro Nóbrega, Paulo Oliveira-Filho, Jamary Maciel Dias, Ronaldo de Oliveira Godeiro Júnior, Clécio Martins Maia, Fernanda Barbosa Thomaz, Rodrigo Santos, Mara Lúcia Sousa de Melo, Eduardo da Nóbrega Júnior, Adaucto Wanderley Lin, Katia Graziani Povoas Barsottini, Orlando Endmayr, Verena Coelho Andrade, Luís Eduardo Höftberger, Romana Almeida Dutra, Lívia |
author_facet | de Freitas Dias, Bruna Fieni Toso, Fabio Slhessarenko Fraife Barreto, Maria Eduarda de Araújo Gleizer, René Dellavance, Alessandra Kowacs, Pedro André Teive, Helio Spitz, Mariana Freire Borges Juliano, Aline Januzi de Almeida Rocha, Letícia Braga-Neto, Pedro Ribeiro Nóbrega, Paulo Oliveira-Filho, Jamary Maciel Dias, Ronaldo de Oliveira Godeiro Júnior, Clécio Martins Maia, Fernanda Barbosa Thomaz, Rodrigo Santos, Mara Lúcia Sousa de Melo, Eduardo da Nóbrega Júnior, Adaucto Wanderley Lin, Katia Graziani Povoas Barsottini, Orlando Endmayr, Verena Coelho Andrade, Luís Eduardo Höftberger, Romana Almeida Dutra, Lívia |
author_sort | de Freitas Dias, Bruna |
collection | PubMed |
description | BACKGROUND: The frequency of antibodies in autoimmune encephalitis (AIE) may vary in different populations, however, data from developing countries are lacking. To describe the clinical profile of AIE in Brazil, and to evaluate seasonality and predictors of AIE in adult and pediatric patients. METHODS: We evaluated patients with possible AIE from 17 centers of the Brazilian Autoimmune Encephalitis Network (BrAIN) between 2018 and 2022. CSF and serum were tested with TBAs and CBAs. Data on clinical presentation, complementary investigation, and treatment were compiled. Seasonality and predictors of AIE in adult and pediatric populations were analyzed. RESULTS: Of the 564 patients, 145 (25.7%) were confirmed as seropositive, 69 (12.23%) were seronegative according to Graus, and 58% received immunotherapy. The median delay to diagnosis confirmation was 5.97 ± 10.3 months. No seasonality variation was observed after 55 months of enrolment. The following antibodies were found: anti-NMDAR (n=79, 54%), anti-MOG (n=14, 9%), anti-LGI1(n=12, 8%), anti-GAD (n=11, 7%), anti-GlyR (n=7, 4%), anti-Caspr2 (n=6, 4%), anti-AMPAR (n=4, 2%), anti-GABA-BR (n=4, 2%), anti-GABA-AR (n=2, 1%), anti-IgLON5 (n=1, 1%), and others (n=5, 3%). Predictors of seropositive AIE in the pediatric population (n=42) were decreased level of consciousness (p=0.04), and chorea (p=0.002). Among adults (n=103), predictors of seropositive AIE were movement disorders (p=0.0001), seizures (p=0.0001), autonomic instability (p=0.026), and memory impairment (p=0.001). CONCLUSION: Most common antibodies in Brazilian patients are anti-NMDAR, followed by anti-MOG and anti-LGI1. Only 26% of the possible AIE patients harbor antibodies, and 12% were seronegative AIE. Patients had a 6-month delay in diagnosis and no seasonality was found. Findings highlight the barriers to treating AIE in developing countries and indicate an opportunity for cost-effect analysis. In this scenario, some clinical manifestations help predict seropositive AIE such as decreased level of consciousness, chorea, and dystonia among children, and movement disorders and memory impairment among adults. |
format | Online Article Text |
id | pubmed-10634608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106346082023-11-10 Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study de Freitas Dias, Bruna Fieni Toso, Fabio Slhessarenko Fraife Barreto, Maria Eduarda de Araújo Gleizer, René Dellavance, Alessandra Kowacs, Pedro André Teive, Helio Spitz, Mariana Freire Borges Juliano, Aline Januzi de Almeida Rocha, Letícia Braga-Neto, Pedro Ribeiro Nóbrega, Paulo Oliveira-Filho, Jamary Maciel Dias, Ronaldo de Oliveira Godeiro Júnior, Clécio Martins Maia, Fernanda Barbosa Thomaz, Rodrigo Santos, Mara Lúcia Sousa de Melo, Eduardo da Nóbrega Júnior, Adaucto Wanderley Lin, Katia Graziani Povoas Barsottini, Orlando Endmayr, Verena Coelho Andrade, Luís Eduardo Höftberger, Romana Almeida Dutra, Lívia Front Immunol Immunology BACKGROUND: The frequency of antibodies in autoimmune encephalitis (AIE) may vary in different populations, however, data from developing countries are lacking. To describe the clinical profile of AIE in Brazil, and to evaluate seasonality and predictors of AIE in adult and pediatric patients. METHODS: We evaluated patients with possible AIE from 17 centers of the Brazilian Autoimmune Encephalitis Network (BrAIN) between 2018 and 2022. CSF and serum were tested with TBAs and CBAs. Data on clinical presentation, complementary investigation, and treatment were compiled. Seasonality and predictors of AIE in adult and pediatric populations were analyzed. RESULTS: Of the 564 patients, 145 (25.7%) were confirmed as seropositive, 69 (12.23%) were seronegative according to Graus, and 58% received immunotherapy. The median delay to diagnosis confirmation was 5.97 ± 10.3 months. No seasonality variation was observed after 55 months of enrolment. The following antibodies were found: anti-NMDAR (n=79, 54%), anti-MOG (n=14, 9%), anti-LGI1(n=12, 8%), anti-GAD (n=11, 7%), anti-GlyR (n=7, 4%), anti-Caspr2 (n=6, 4%), anti-AMPAR (n=4, 2%), anti-GABA-BR (n=4, 2%), anti-GABA-AR (n=2, 1%), anti-IgLON5 (n=1, 1%), and others (n=5, 3%). Predictors of seropositive AIE in the pediatric population (n=42) were decreased level of consciousness (p=0.04), and chorea (p=0.002). Among adults (n=103), predictors of seropositive AIE were movement disorders (p=0.0001), seizures (p=0.0001), autonomic instability (p=0.026), and memory impairment (p=0.001). CONCLUSION: Most common antibodies in Brazilian patients are anti-NMDAR, followed by anti-MOG and anti-LGI1. Only 26% of the possible AIE patients harbor antibodies, and 12% were seronegative AIE. Patients had a 6-month delay in diagnosis and no seasonality was found. Findings highlight the barriers to treating AIE in developing countries and indicate an opportunity for cost-effect analysis. In this scenario, some clinical manifestations help predict seropositive AIE such as decreased level of consciousness, chorea, and dystonia among children, and movement disorders and memory impairment among adults. Frontiers Media S.A. 2023-10-25 /pmc/articles/PMC10634608/ /pubmed/37954587 http://dx.doi.org/10.3389/fimmu.2023.1256480 Text en Copyright © 2023 de Freitas Dias, Fieni Toso, Slhessarenko Fraife Barreto, de Araújo Gleizer, Dellavance, Kowacs, Teive, Spitz, Freire Borges Juliano, Januzi de Almeida Rocha, Braga-Neto, Ribeiro Nóbrega, Oliveira-Filho, Maciel Dias, de Oliveira Godeiro Júnior, Martins Maia, Barbosa Thomaz, Santos, Sousa de Melo, da Nóbrega Júnior, Lin, Graziani Povoas Barsottini, Endmayr, Coelho Andrade, Höftberger and Almeida Dutra https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology de Freitas Dias, Bruna Fieni Toso, Fabio Slhessarenko Fraife Barreto, Maria Eduarda de Araújo Gleizer, René Dellavance, Alessandra Kowacs, Pedro André Teive, Helio Spitz, Mariana Freire Borges Juliano, Aline Januzi de Almeida Rocha, Letícia Braga-Neto, Pedro Ribeiro Nóbrega, Paulo Oliveira-Filho, Jamary Maciel Dias, Ronaldo de Oliveira Godeiro Júnior, Clécio Martins Maia, Fernanda Barbosa Thomaz, Rodrigo Santos, Mara Lúcia Sousa de Melo, Eduardo da Nóbrega Júnior, Adaucto Wanderley Lin, Katia Graziani Povoas Barsottini, Orlando Endmayr, Verena Coelho Andrade, Luís Eduardo Höftberger, Romana Almeida Dutra, Lívia Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title | Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title_full | Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title_fullStr | Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title_full_unstemmed | Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title_short | Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study |
title_sort | brazilian autoimmune encephalitis network (brain): antibody profile and clinical characteristics from a multicenter study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634608/ https://www.ncbi.nlm.nih.gov/pubmed/37954587 http://dx.doi.org/10.3389/fimmu.2023.1256480 |
work_keys_str_mv | AT defreitasdiasbruna brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT fienitosofabio brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT slhessarenkofraifebarretomariaeduarda brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT dearaujogleizerrene brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT dellavancealessandra brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT kowacspedroandre brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT teivehelio brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT spitzmariana brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT freireborgesjulianoaline brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT januzidealmeidarochaleticia brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT braganetopedro brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT ribeironobregapaulo brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT oliveirafilhojamary brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT macieldiasronaldo brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT deoliveiragodeirojuniorclecio brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT martinsmaiafernanda brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT barbosathomazrodrigo brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT santosmaralucia brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT sousademeloeduardo brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT danobregajunioradauctowanderley brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT linkatia brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT grazianipovoasbarsottiniorlando brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT endmayrverena brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT coelhoandradeluiseduardo brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT hoftbergerromana brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy AT almeidadutralivia brazilianautoimmuneencephalitisnetworkbrainantibodyprofileandclinicalcharacteristicsfromamulticenterstudy |